Vasogen (MM) (VSGN) ニュース

What a nice pump and dump....

I expect VSGN to explode shortly. Their merger with Intellipharmaceutics is a marriage in heaven.

A lot more than just simple TA behind this thing...

fell of its 3-month high in early morning trading..any news or expectations that we should know about?

surge into the close .25!!

after-market ask is at .47....lets see what happens tomorrow

quiet board for a decent trading day...does anyone know what the future developments are? i know they came out with a press release today but it wasn't very specific.

Short Interest...Short History:

Jul 31, 2008 75,691 -12.51 48,337 1.57 No No
Jul 15, 2008 86,515 11.07 54,245 1.59 No No
Jun 30, 2008 77,895 -0.16 99,912 1.00 No No
Jun 13, 2008 78,017 2.13 52,946 1.47 No No
May 30, 2008 76,387 -0.46 104,079 1.00 No No
May 15, 2008 76,742 -26.44 130,224 1.00 No No
Apr 30, 2008 104,332 -7.28 140,567 1.00 No No
Apr 15, 2008 112,521 -9.40 122,340 1.00 No No
Mar 31, 2008 124,192 -7.72 133,780 1.00 No No
Mar 14, 2008 134,579 43.71 193,220 1.00 No No

*DD*

"Our research and development initiatives have resulted in the filing of numerous patent applications. We currently have 30 U.S. patents and over 275 patents issued in other jurisdictions."

Website:

http://www.vasogen.com

"Our focus has been on the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neuro-inflammatory disorders. We are not currently advancing the development of our products and are focused on exploring strategic options that may include a sale of the Company to a third party, merger, an acquisition by us, or other strategic alternative."

9/10/08

Last Sale 0.29 Change -0.00
% Change -0.000003 Tick Down
Daily High 0.32 Daily Low 0.28
Opening Price 0.2813 Volume 81,646
52 wk. High 2.68 52 wk. Low 0.261
Prev Close 0.29 Dividend 0.00
Yield 0.00 Beta Coefficient 0.73
Earnings/Share -1.07 P/E Ratio

Just a few buys at eod?????
http://ih.advfn.com/p.php?pid=trades&cb=1219994854&symbol=A%5ESGN
Im in 2morrow

This has a real pretty chart.

Came up on scan


VSGN

Pincher breaking out

Vasogen Provides Update on ACCLAIM II Program
Monday March 3, 9:06 am ET

MISSISSAUGA, ON, March 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News) today provided an update on ACCLAIM II, a clinical trial which is being planned to support an application for U.S. market approval of the Celacade(TM) System for the treatment of patients with New York Heart Association (NYHA) Class II heart failure.

The Company announced in December that the FDA was examining its internal jurisdiction over Vasogen's Celacade System in the context of a newly issued draft guidance document to assess whether this document was relevant to Celacade. Previously, the FDA's Center for Devices and Radiological Health (CDRH) acted as lead reviewer of Celacade, with input from the Center for Biologics Evaluation and Research (CBER). The FDA has confirmed that Celacade will remain regulated as a medical device; however, CBER will be the lead reviewer of the Celacade technology, with CDRH providing input. The transition process from CDRH to CBER is now complete.

As part of the transition, on February 29, CDRH communicated to the Company that they now disagree with the use of a Bayesian approach because of a concern with recruiting a heterogeneous study population between ACCLAIM and ACCLAIM II. This is contrary to the FDA's original communication to Vasogen recommending a Bayesian study design, and, as part of its ongoing informal dialogue, the Company plans to provide the FDA with its position regarding the ACCLAIM II study population.

"The FDA's comments with respect to utilizing a Bayesian approach for the design of ACCLAIM II are surprising," commented Chris Waddick, President and CEO of Vasogen. "Our immediate focus will be to engage in discussions with the FDA to clarify their position on the proposed ACCLAIM II study protocol and statistical analysis plan and to work with members of the ACCLAIM II Steering Committee and our statistical advisors to address the FDA's concerns. We will provide an update to shareholders once we have had further discussions with the FDA."

Vasogen retained Berry Consultants and Dr. Donald A. Berry, Head, Division of Quantitative Sciences and Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, and a world recognized authority in the area of Bayesian and adaptive trial design. Dr. Berry has been assisting Vasogen throughout the development of ACCLAIM II study design. Vasogen has also established the ACCLAIM II Steering Committee led by James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure, appointed Chairs for the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee (CEC), and has drafted the key trial documents necessary to initiate the trial. The Company has also selected a CRO and has identified and received commitments from U.S.-based clinical sites to participate in the study. The majority of these sites participated in the first ACCLAIM trial and were selected on the basis of their ability to quickly recruit patients and conduct high quality research.

Vasogen's Research Published in European Journal of Neuroscience
Monday January 28, 7:00 am ET
- VP025 Provides a Neuroprotective Effect in Preclinical Model of Parkinson's Disease -

MISSISSAUGA, ON, Jan. 28 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders, today announced the publication of preclinical findings demonstrating that Vasogen's VP025, the leading candidate from its VP series of drugs, provides a significant neuroprotective effect in a model of Parkinson's disease. The research, which was conducted at the University College Cork, Ireland, was published in the European Journal of Neuroscience (Vol 27, pp.294-300, 2008).

Evidence is accumulating that inflammation plays an important role in the pathogenesis of Parkinson's disease. Microglial cells (immune cells resident in the brain) are activated in Parkinson's disease, producing pro-inflammatory factors that result in the death of nerve cells in an area of the brain called the nigrostriatal pathway. The published research was based on a well-established model of Parkinson's disease that involves the generation of a lesion on one side of the brain by the introduction of 6-hydroxydopamine (6-OHDA), inducing abnormal behaviour resulting in rotational movement. Both Parkinson's disease and 6-OHDA administration are associated with inflammatory processes that lead to the death of certain nerve cells, the dopaminergic neurons, which produce the neurotransmitter dopamine. It is the loss of these neurons and thereby the dopamine they produce that results in the movement abnormalities seen in this model.

The published study assessed the effect of pre-treatment with VP025 on 6-OHDA-induced rotational behaviour in response to amphetamine. Treatment with VP025 prior to 6-OHDA administration led to behavioural improvement demonstrated by a substantial (50-75%) and significant (p<0.001) reduction in rotation rate. VP025 also protected against the loss of dopaminergic neurons and provided significant protection against the reduction in levels of striatal dopamine induced by OHDA. The absence of rotations was maintained for up to three weeks while partial protection against the loss of dopaminergic neurons and reduction in striatal dopamine levels was still evident four weeks after lesion induction, indicating that VP025 has a potential long-term neuroprotective effect in this model.

http://biz.yahoo.com/prnews/080128/to401.html?.v=34

More news : Results of Vasogen's Phase III ACCLAIM Trial Accepted for Publication in The Lancet

Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
Monday December 17, 9:25 am ET

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark approved product that specifically targets the destructive chronic inflammation underlying the development and progression of chronic heart failure. Under the CE Mark, Celacade can be marketed in the 27 countries that comprise the European Union and is indicated in the EU for the treatment of New York Heart Association (NYHA) Class II patients and NYHA Class II, III, & IV heart failure patients who do not have a prior history of heart attack.
http://biz.yahoo.com/prnews/071217/to444.html?.v=31

Hi Surf,

It seems that everything I buy recently you own the stock and/or moderate the board, very funny )

Just to let you know that I bought a few shares today. From a TA perspective it looks like VSGN is nearly oversold.
Hopefully VSGN releases some decent news for the stock to reverse.

Cheers

Vasogen Announces Third Quarter 2007 Results

MISSISSAUGA, ON, Oct. 9 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the third quarter of 2007. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At August 31, 2007, our cash and cash equivalents and restricted cash totaled $29.1 million, compared with $33.8 million at May 31, 2007. With the repayment of our convertible notes during the second quarter, we no longer have any restricted cash. The change in our cash position resulted mainly from cash used for operations. Our net cash used for operations for the three months ended August 31, 2007, was $4.4 million.

The net loss for the third quarter of 2007 was $5.3 million, or $0.24 per common share, compared with a net loss of $14.6 million, or $1.55 per common share for the same period in 2006. We incurred a net loss for the nine months ended August 31, 2007 of $22.7 million, or $1.21 per common share, compared with a net loss of $56.3 million, or $6.41 per common share for the same period in 2006. The key drivers of our reduced losses in 2007 are lower costs associated with the completion of our phase III clinical programs, the corporate costs associated with supporting these programs, and a reduction in expenses associated with our senior convertible notes which has been partially offset by restructuring costs. The difference between cash used in operations and our accounting loss is driven by non-cash items, such as expenses related to our senior convertible notes and stock options, as well as unrealized foreign exchange gains and losses.

Highlights

- Following our meeting with the Food and Drug Administration (FDA) in
May 2007 regarding our ACCLAIM results, the agency strongly
recommended that we conduct a confirmatory trial ('ACCLAIM-II') of
Celacade in NYHA Class II heart failure patients to support a
Pre-market Approval submission for the purpose of achieving
regulatory approval in the United States. The FDA also recommended
that we use a Bayesian approach in the design of the confirmatory
trial. The FDA indicated that they were recommending this approach
specifically because it would allow us to borrow power from the
ACCLAIM trial and also because it has the potential to substantially
reduce the sample size required for a confirmatory study. The planned
trial design for ACCLAIM-II indicates that as few as 300 patients
could provide sufficient data to confirm the finding of the
phase III ACCLAIM trial which demonstrated a 39% reduction
(p=0.0003) in the risk of death or cardiovascular
hospitalizations for patients receiving Celacade in the large
pre-specified subgroup of 689 NYHA class II heart failure patients.
Furthermore, the use of an adaptive clinical trial design also
provides the flexibility to increase the sample size up to
600 patients, should additional data be required. We are preparing to
meet with the FDA again, with the objective of obtaining formal
regulatory agreement with respect to our proposed trial design prior
to the end of the year.

- James B. Young, MD, Chairman, Division of Medicine at the Cleveland
Clinic Foundation and Medical Director, Kaufman Center for Heart
Failure, has agreed to be the Global Principal Investigator and
Chairman of the Steering Committee for the planned ACCLAIM-II study.
Dr. Young, who has played a leading role in numerous multi-center
clinical trials focusing on heart failure and transplantation, led
Vasogen's 2,400-patient ACCLAIM study, which was completed last year.
We are also pleased to announce the other members of the newly formed
ACCLAIM-II steering committee include Guillermo Torre-Amione, MD,
PhD, FACC, Medical Director, Heart Transplant Program, Methodist
DeBakey Heart Center at The Methodist Hospital; Robert Bourge, MD,
Professor & Director of Cardiology Division, Department of Medicine,
University of Alabama at Birmingham; Jean Rouleau, MD, Dean of
Medicine, University of Montreal; Maria Rosa Costanzo, MD, Medical
Director, Edward Center for Heart Failure, Midwest Heart Foundation;
Clyde W. Yancy Jr., MD, Medical Director, Baylor Heart & Vascular
Institute; and Mariell Jessup, MD, Medical Director, Hospital of the
University of Pennsylvania, Heart Failure/Transplant Center.

- A medical symposium focused on the introduction of our
Celacade technology into the European Union was recently held during
the 11th National Conference of Advanced Therapies in Heart Failure
in Spain. The symposium, which was hosted by our European
commercialization partner, Grupo Ferrer Internacional, S.A.
('Ferrer'), was attended by physicians whom Ferrer is targeting to
participate in the initial roll-out of our Celacade technology for
the treatment of heart failure patients. Ferrer is initially
targeting Germany and Spain for the initial commercial launch of
Celacade. Among the presenters at the symposium was Dr. Torre-Amione,
who discussed the importance of the role inflammation plays in the
development and progression of heart failure, and who also reviewed
the results of the ACCLAIM trial of Celacade in chronic heart
failure. The European commercialization activities for Celacade are
proceeding as planned and we remain on track with our objective of
launching Celacade in Europe before the end of the year.

- Today we announced that a recently published book,
'Immune Dysfunction and Immunotherapy in Heart Disease,' discusses
the Celacade System for the treatment of heart failure. The chapter
entitled 'Anti-inflammatory therapy in heart failure,' describes how
the growing understanding of the role inflammation in heart failure
has led to new treatment modalities and describes the potential of
Celacade to target this underlying pathology. The authors of the
chapter describe the mechanism of action of Celacade and review the
results of the ACCLAIM trial. Regarding the results of the trial, the
authors state: 'These findings are consistent with the role that
chronic inflammation plays in the development and progression of HF
and are particularly impressive in the large subgroup of
NYHA Class III or IV patients who had not experienced a prior heart
attack and in all NYHA class II patients. These results provide a
strong basis for targeting Celacade's novel anti-inflammatory
mechanism in this large and well-defined patient population.'

As previously announced, a conference call will be conducted on October 9, 2007, at 4:30 p.m. Eastern time. The conference call may be accessed by calling 416-641-6124 or 1-866-300-4047 ten minutes prior to the call. An audio web cast of the event will also be available at www.vasogen.com. A re-broadcast of the conference call may be accessed by calling 416-695-5800 or 1-800-408-3053, PIN code 3238234 followed by the number sign, and will also be available at www.vasogen.com.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Certain statements contained in this press release, the upcoming conference call and web cast, or elsewhere in our public documents constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or 'forward-looking information' under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'expects', 'plans', 'anticipates', 'believes', 'estimated', 'predicts', 'potential', 'continue', 'intends', 'could', or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the 'Risk Factors' section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The unaudited interim consolidated financial statements, accompanying notes to the unaudited interim consolidated financial statements, and Management's Discussion and Analysis for the three months and nine months ended August 31, 2007, will be accessible on Vasogen's Website at www.vasogen.com and will be available on SEDAR and EDGAR. Summary financial tables are provided below.


VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Balance Sheets
(In thousands of Canadian dollars)

-------------------------------------------------------------------------
August 31, November 30,
2007 2006
-------------------------------------------------------------------------
(Unaudited)
Assets

Current assets:
Cash and cash equivalents $ 29,121 $ 30,427
Restricted cash - 6,403
Clinical supplies 1,241 1,211
Tax credits recoverable 1,356 1,327
Prepaid expenses and deposits 583 1,384
-----------------------------------------------------------------------
32,301 40,752

Property and equipment 476 615

Acquired technology 63 253

Deferred financing costs - 150

-------------------------------------------------------------------------
$ 32,840 $ 41,770
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities:
Accounts payable $ 537 $ 3,369
Accrued liabilities 3,267 5,067
Senior convertible notes payable - 8,754
-----------------------------------------------------------------------
3,804 17,190
Shareholders' equity:
Share capital:
Authorized:
Unlimited common shares, without par value
Issued and outstanding:
22,391,387 common shares
(November 30, 2006 - 15,665,134) 365,670 344,217
Stock-based compensation 10,958 10,713
Equity component of senior convertible
notes payable - 1,639
Warrants 16,725 11,390
Contributed surplus 11,408 7,995
Deficit (375,725) (351,374)
-----------------------------------------------------------------------
29,036 24,580

Commitments and contingencies
-------------------------------------------------------------------------
$ 32,840 $ 41,770
-------------------------------------------------------------------------
-------------------------------------------------------------------------



VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Statements of Operations, Deficit and Comprehensive
Income
(In thousands of Canadian dollars, except per share amounts)
(Unaudited)

-------------------------------------------------------------------------
Period from
December 1,
Three months ended Nine months ended 1987 to
August 31, August 31, August 31,
2007 2006 2007 2006 2007
-------------------------------------------------------------------------
Expenses:
Research and
development $ 2,588 $ 7,360 $ 9,347 $ 29,773 $ 238,028
General and
administration 2,887 3,800 11,363 14,290 116,535
Foreign exchange
loss (gain), net 242 (12) 1,200 160 10,193
-------------------------------------------------------------------------

Loss before the
undernoted (5,717) (11,148) (21,910) (44,223) (364,756)

Interest expense on
senior convertible
notes payable - (116) (5) (903) (1,279)

Accretion in
carrying value of
senior convertible
notes payable - (1,727) (728) (6,633) (10,294)

Amortization of
deferred financing
costs - (577) (154) (2,157) (3,057)

Loss on
extinguishment of
senior convertible
notes payable - (1,407) (1,754) (4,101) (6,749)

Investment income 370 409 1,003 1,681 13,018

Change in fair value
of embedded
derivatives - - 829 - 829
-------------------------------------------------------------------------

Loss for the period
and comprehensive
loss (5,347) (14,566) (22,719) (56,336) (372,288)

Deficit, beginning of
period:
As previously
reported (370,378) (326,784) (351,374) (284,719) (1,510)
Impact of change
in accounting for
financial
instruments on
December 1, 2006 - - (1,632) - (1,632)
-----------------------------------------------------------------------

As restated (370,378) (326,784) (353,006) (284,719) (3,142)

Charge for
acceleration
payments on equity
component of senior
convertible notes
payable - - - (295) (295)

-------------------------------------------------------------------------
Deficit, end of
period $(375,725) $(341,350) $(375,725) $(341,350) $(375,725)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted
loss per share $ (0.24) $ (1.55) $ (1.21) $ (6.41) $ -

-------------------------------------------------------------------------
-------------------------------------------------------------------------



VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Statements of Cash Flows
(In thousands of Canadian dollars)
(Unaudited)

-------------------------------------------------------------------------
Period from
December 1,
Three months ended Nine months ended 1987 to
August 31, August 31, August 31,
2007 2006 2007 2006 2007
-------------------------------------------------------------------------
Cash provided by
(used in):
Operations:
Loss for the
period $ (5,347) $ (14,566) $ (22,719) $ (56,336) $(372,288)
Items not
involving cash:
Amortization 125 146 378 444 6,034
Accretion in
carrying value
of senior
convertible
notes payable - 1,727 728 6,633 10,294
Amortization of
deferred
financing costs - 577 154 2,157 3,057
Loss on
extinguishment
of senior
convertible
notes payable - 1,407 1,754 4,101 6,749
Change in fair
value of
embedded
derivatives - - (829) - (829)
Stock-based
compensation 164 774 1,615 2,456 13,207
Common shares
issued for
services - 28 - 28 2,485
Unrealized
foreign
exchange loss
(gain) 227 (121) 1,454 585 10,431
Other - - - - (35)
Change in
non-cash
operating working
capital 413 (5,184) (3,890) (13,832) 595
-----------------------------------------------------------------------
(4,418) (15,212) (21,355) (53,764) (320,300)
Financing:
Shares and warrants
issued for cash - - 17,345 - 326,358
Warrants exercised
for cash - - - - 16,941
Options exercised
for cash - - - - 7,669
Share issue costs - (160) (1,440) (160) (24,646)
Issue (repayment)
of senior
convertible notes
payable, net - (1,695) (924) (3,810) 38,561
Restricted cash 3,078 (38) 6,403 648 -
Cash payment on
acceleration
warrants exercise
price - - - (49) (49)
Paid to related
parties - - - - (234)
-----------------------------------------------------------------------
3,078 (1,893) 21,384 (3,371) 364,600
Investments:
Purchase of
property and
equipment (8) (10) (49) (24) (2,465)
Purchase of
acquired
technology - - - - (1,283)
Purchases of
marketable
securities - - - (80) (244,846)
Settlement of
forward exchange
contracts - - 10 (259) (4,824)
Maturities of
marketable
securities - - - 22,877 240,677
-----------------------------------------------------------------------
(8) (10) (39) 22,514 (12,741)
Foreign exchange
gain (loss) on cash
held in foreign
currency (227) 205 (1,296) (1,334) (2,438)
-------------------------------------------------------------------------
Increase (decrease)
in cash and cash
equivalents (1,575) (16,910) (1,306) (35,955) 29,121
Cash and cash
equivalents,
beginning of period 30,696 31,476 30,427 50,521 -
-------------------------------------------------------------------------
Cash and cash
equivalents, end
of period $ 29,121 $ 14,566 $ 29,121 $ 14,566 $ 29,121
-------------------------------------------------------------------------
-------------------------------------------------------------------------



SOURCE Vasogen Inc.

Source: PR Newswire (October 9, 2007 - 3:10 PM EST)

News by QuoteMedia
www.quotemedia.com

Bullish MACD Crossovers (VSGN)

P&F Descending Triple Bottom Alerts (VSGN)

Improving Chaikin Money Flow (VSGN)

Vasogen Plans Confirmatory Study of Celacade(TM) in Chronic Heart Failure to Support U.S. Regulatory Approval

MISSISSAUGA, ON, Sept. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced plans for a confirmatory study that would support an application for regulatory approval in the United States of its Celacade technology for the treatment of patients with NYHA Class II heart failure. The planned trial design indicates that as few as 300 patients could provide sufficient data to confirm the finding of the phase III ACCLAIM trial which demonstrated a 39% reduction (p equals 0.0003) in the risk of death or cardiovascular hospitalizations for the large pre-specified subgroup of 689 NYHA class II heart failure patients.

'We are extremely pleased with the proposed design for a confirmatory trial of Celacade in patients diagnosed with NYHA Class II heart failure. For the purpose of obtaining U.S. regulatory approval, an adaptive trial design utilizing a Bayesian statistical approach provides us with the possibility of confirming our earlier results with as few as 300 patients,' commented Chris Waddick, President and CEO of Vasogen. 'We are now preparing to meet with the FDA, with the objective of obtaining formal FDA agreement with respect to our proposed trial design prior to the end of the year. Furthermore, we continue to be on track for the initial commercialization of Celacade by year-end in the European Union, where Celacade has already received CE Mark regulatory approval for the treatment of NYHA Class II heart failure.'

In May, Vasogen met with the FDA to review the ACCLAIM trial data, which demonstrated a 39% reduction (p equals 0.0003) in the risk of death and cardiovascular hospitalizations for the large pre-specified subgroup of 689 NYHA class II heart failure patients. As a result of the meeting, the FDA strongly recommended that Vasogen conduct a confirmatory study to support a U.S. Pre-Market Approval filing for Celacade for NYHA Class II heart failure patients and also recommended that the Company consider utilizing a Bayesian approach. This approach involves a trial design methodology that allows utilization of prior trial results to contribute to the statistical power of a confirmatory study and therefore provides the opportunity to significantly reduce the number of required patients, as well as the cost and duration of the study. As a result of the FDA's recommendations, Vasogen retained Berry Consultants and Dr. Donald A. Berry, Head, Division of Quantitative Sciences and Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, and a world recognized authority in the area of Bayesian and adaptive trial design, to assist with the development of a confirmatory study. The proposed trial design indicates that as few as 300 patients could provide sufficient data to confirm the finding of the ACCLAIM trial. Furthermore, the use of an adaptive clinical trial design also provides the flexibility to increase the sample size up to 600 patients should additional data be required.

As in Vasogen's ACCLAIM study, it is expected that the primary endpoint of the planned study will be death or first cardiovascular hospitalization. The double-blind, placebo-controlled study is also expected to have similar inclusion/exclusion criteria as ACCLAIM, with all patients on standard-of-care medication for heart failure. If successful, this trial is expected to support an application for regulatory approval in the United States of Vasogen's Celacade technology for the treatment of patients with NYHA Class II heart failure. The final study design and sample size are subject to approval by the FDA. The Company is in the process of establishing a Steering Committee that will provide input to the final study design, which will then be subject to approval by the FDA.

Heart failure, most frequently resulting from coronary artery disease or hypertension, is a debilitating syndrome in which the heart's ability to function as a pump is impaired. Patients with heart failure experience a continuing decline in their health, resulting in an increased frequency of hospitalization and premature death. According to the Heart Failure Society of America, heart failure is the only major cardiovascular disease with prevalence and incidence on the rise. Heart failure, which is now often referred to as an epidemic, is estimated to affect 12 million individuals in North America and Europe, and an estimated 4.4 million have NYHA Class II symptomatic impairment.

About Celacade:

Therapy utilizing the Celacade technology targets the inflammation underlying chronic heart failure and other cardiovascular diseases. Inflammation is a normal response of the immune system to cellular injury caused by infection, trauma, or other stimuli. During the inflammatory process, immune cells release a number of factors, including cytokines - potent chemical messengers that modulate inflammation and facilitate the healing process. While this inflammatory process is usually self-limiting, it can persist, become chronic, and lead to a number of serious medical conditions.

During a brief outpatient procedure, a small sample of a patient's blood is drawn into Vasogen's Celacade single-use disposable cartridge and exposed to controlled oxidative stress utilizing Vasogen's proprietary Celacade medical device technology. Oxidative stress is a factor known to initiate apoptosis, a physiologic process that is inherently anti-inflammatory. The treated blood is then administered to the same patient intramuscularly. An initial course of treatment comprising three consecutive outpatient procedures is administered over a two-week period, and treatments are continued once per month thereafter.

Hammer Patterns (VSGN)

Improving Chaikin Money Flow (VSGN)

They are what they are(sometimes they are just short term signals, but when you several coming in together it can be a forecaster of a continued direction)

these charts no longer work in manipulated markets.

Parabolic SAR Buy Signals (VSGN)

Bullish Engulfing Patterns (VSGN) from nightly stockcharts.com scan

Stocks in a New Uptrend (Aroon) (VSGN) & Parabolic SAR Buy Signals (VSGN) from stockcharts.com nightly scan

If that happens today then I am a seller at $3.15 or higher.

VSGN just broke through its overhang & $3.20 should be next.

Nice breakaway gap this morning with VSGN & with no news(should have added more)

The best part is the decrease in losses, not that I am happy with a 9 mil loss but it was 24 mil at this time last year. Still plenty of cash on hand 30 mil so that should be ok of another year or so but they will need to raise capital soon and lets just hope its at much higher prices.

From a Yahoo poster who claims to be a biotech news writer/anal-list(take it for what its worth)

>>Although I am not familiar with what (exactly) goes into formulating a price target, my guess would be that it is probably complex in nature>>>

Well, I can try to help you out on that one. I am a professional biotech investor and I even run a weekly biotech newsletter to a range of danish subscribers.

The targets you see from analysts are based on DCF-modelling (Discounted Cash Flow modelling), which basically translates expected future cash flow into a Net Present Value (therefore also called NPV-modeling).

I have updated my target for Vasogen last night following the Conference Call. My new target is $38,94/share

Here is how I calculate it:

NET CASH POSITION PER SHARE EVALUATION
Number of outstanding shares: 22.391.402
Cash position: $32,25 million (equals to 33,8 million canadian dollars)
Cash position per share: $1,44/share

$1,44/share is equal to the net cash position as Vasogen has now paid off all convertible debt.

PIPELINE EVALUATION
Program: Celacade Europe/Latin America
Disease target: Chronic Heart Failure
Partner: Grupo Ferrer
Probability: 100% (already approved therefore 100%)
Market launch: 2008
Years on market: 10
Peak Sale ramp up period (years): 6
Peak sale: $1000 million
Estimated Net royalty rate: 27%
WACC: 15%
Net Present Value: $635 million
NPV per share: $28,35/share

Program: Celacade United States
Disease target: Chronic Heart Failure (NYHA Class II only)
Partner: Own program
Probability: 25%
Market launch: 2011
Years on market: 10
Peak Sale ramp up period (years): 4
Peak sale: $500 million
Estimated Net royalty rate: 60%
WACC: 15%
Net Present Value: $167 million
NPV per share: $7,46/share

Program: VP025
Disease target: Diabetic Retinopathy
Partner: Own program
Probability: 15%
Market launch: 2013
Years on market: 10
Peak Sale ramp up period (years): 4
Peak sale: $250 million
Estimated Net royalty rate: 60%
WACC: 15%
Net Present Value: $38 million
NPV per share: $1,69/share


TOTAL NET PRESENT VALUE OF VASOGEN PER SHARE
Net cash position: $1,44/share
Celacade Europe/Latin America: $28,35/share
Celacade United States: $7,46/share
VP025: $1,69/share
Total value: $38,94/share

Vasogen Announces Second Quarter 2007 Results

MISSISSAUGA, ON, July 10 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the second quarter of 2007. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At May 31, 2007, our cash and cash equivalents and restricted cash totaled $33.8 million, compared with $36.8 million at November 30, 2006, and $27.4 million at February 28, 2007. The change in our cash position resulted from net proceeds of $15.4 million from our May 2007 financing, partially offset by cash used for operations. Our net cash used in operations for the three months and six months ended May 31, 2007, was $7.9 million and $16.9 million, respectively. The net cash used in operations includes restructuring costs for the three months and six months ended May 31, 2007 of $2.5 million and $2.9 million, respectively.

As of April 1, 2007, the outstanding principal balance of our senior convertible notes was fully repaid. From September 1, 2006, we were required, under the terms of the convertible notes, to maintain a balance of cash, including restricted cash and marketable securities, equal to 110% of the convertible notes outstanding. We satisfied this cash test at all times. With the repayment of our convertible notes during this quarter, the remaining balance of our restricted cash will become unrestricted during the third quarter.

The net loss for the second quarter of 2007 was $9.7 million, or $0.54 per common share, compared with a net loss of $22.4 million, or $2.59 per common share for the same period in 2006. We incurred a net loss for the six months ended May 31, 2007 of $17.4 million, or $1.02 per common share, compared with a net loss of $41.8 million, or $4.93 per common share for the same period in 2006. The key drivers of our reduced losses in 2007 are lower costs associated with the completion of our phase III clinical programs, the corporate costs associated with supporting these programs, and a reduction in expenses associated with our senior convertible notes. The difference between cash used in operations and our accounting loss is driven by non-cash items, such as certain expenses related to our senior convertible notes, stock option expense, and unrealized foreign exchange gains and losses.

Vasogen is also today announcing the appointment of Graham D. Neil, CA, to the position of Chief Financial Officer. Mr. Neil has served with Vasogen for over seven years and has played a progressive and integral role in Vasogen's internal control, financial management and reporting. He joined the Company as Controller in 1999 and most recently served as Director of Finance. Mr. Neil holds a Chartered Accountant designation and prior to joining Vasogen, he was with KPMG, LLP.

Highlights

- On June 27, 2007, we announced the outcome of a meeting with the Food
and Drug Administration (FDA) regarding the next steps in the
development of our Celacade technology for the treatment of chronic
heart failure in the United States. During the meeting, we discussed
with the FDA the results of the ACCLAIM study, with a particular
focus on the 689-patient subgroup with NYHA Class II heart failure.
As a result of this meeting, the FDA has strongly recommended that we
conduct a confirmatory study to support a Pre-market Approval (PMA)
filing and also recommended that we consider utilizing a Bayesian
statistical approach to designing the confirmatory trial. The
Bayesian approach involves a specific trial methodology that allows
utilization of prior trial results with a confirmatory study to
obtain additional information regarding efficacy and safety and has
the potential to substantially reduce the number of patients required
for a confirmatory study, as well as the cost and duration. Having
received the FDA's input, we are now in a position to fully evaluate
our options with respect to a confirmatory trial that could
potentially be smaller than the 689-patient NYHA Class II subgroup of
patients in ACCLAIM if we elected a Bayesian approach. We are
continuing our ongoing dialogue with the FDA, as well as consulting
our statistical experts and other advisors to review trial design
options.

- On June 20, 2007, we announced that Chris Waddick, MBA, CMA,
succeeded Terrance H. Gregg as President and CEO of our Company.
Mr. Waddick, who previously served as Chief Operating Officer and
Chief Financial Officer, has held a series of progressive senior
management positions at Vasogen over the past twelve years. During
his tenure, he has played a key role in our development and strategic
direction and has been responsible for operations since 2005. Mr.
Waddick was also appointed to Vasogen's Board of Directors. In March
2007, Mr. Gregg succeeded David G. Elsley as President and Chief
Executive Officer of Vasogen. Mr. Gregg, who has served on our Board
of Directors since 1999, and who was appointed Chairman in March
2006, remains Chairman of Vasogen's Board of Directors.

- On May 24, 2007, we announced the closing of a financing for net
proceeds of $15.4 million through the sale of our common shares to
institutional investors at a price of US$3.25. Under the terms of the
purchase agreements, we also issued 5-year warrants to purchase an
additional 3.7 million common shares at an exercise price of US$3.16
per share.

- On April 18, 2007 we announced a collaboration with Grupo Ferrer
Internacional, S.A., a leading European pharmaceutical and medical
devices company, to commercialize Vasogen's Celacade technology for
the treatment of chronic heart failure in specified countries of the
European Union and in certain Latin American countries.

As previously announced, a conference call will be conducted on July 10, 2007, at 4:30 p.m. Eastern time. The conference call may be accessed by calling 416-695-6623 or 1-877-461-2814 ten minutes prior to the call. An audio web cast of the event will also be available at www.vasogen.com. A re-broadcast of the conference call may be accessed by calling 416-641-2130 or 1-888-330-1923, PIN code 6543 followed by the number sign, and will also be available at www.vasogen.com

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) technology, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade(TM) is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and is preparing to advance VP025, the lead drug candidate from this new class, into phase II development.

Certain statements contained in this press release, the upcoming conference call and webcast, or elsewhere in our public documents constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or 'forward-looking information' under the Securities Act (Ontario). These statements may include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, plans to advance the development of Celacade(TM), plans to fund our current activities, statements concerning our partnering activities and health regulatory submissions, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'expects', 'plans', 'anticipates', 'believes', 'estimated', 'predicts', 'potential', 'continue', 'intends', 'could', or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trails, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the 'Risk Factors' section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Unless otherwise indicated, numerical values indicating the statistical significance ('p-values') of results included in this document are based on analyses that do not account for endpoint multiplicity.

The unaudited interim consolidated financial statements, accompanying notes to the unaudited interim consolidated financial statements, and Management's Discussion and Analysis for the three months and six months ended May 31, 2007, will be accessible on Vasogen's Website at www.vasogen.com and will be available on SEDAR and EDGAR. Summary financial tables are provided below.

VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Balance Sheets
(In thousands of Canadian dollars)

-------------------------------------------------------------------------
May 31, November 30,
2007 2006
-------------------------------------------------------------------------
(Unaudited)
Assets

Current assets:
Cash and cash equivalents $ 30,696 $ 30,427
Restricted cash 3,078 6,403
Clinical supplies 1,248 1,211
Tax credits recoverable 1,330 1,327
Prepaid expenses and deposits 779 1,384
-----------------------------------------------------------------------
37,131 40,752

Property and equipment 529 615

Acquired technology 127 253

Deferred financing costs - 150
-------------------------------------------------------------------------
$ 37,787 $ 41,770
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities:
Accounts payable $ 896 $ 3,369
Accrued liabilities 2,672 5,067
Senior convertible notes payable - 8,754
-----------------------------------------------------------------------
3,568 17,190

Shareholders' equity
Share capital:
Authorized:
Unlimited common shares, without par value
Issued and outstanding:
22,391,402 common shares
(November 30, 2006 - 15,665,134) 365,670 344,217
Stock-based compensation 10,950 10,713
Equity component of senior convertible
notes payable - 1,639
Warrants 16,725 11,390
Contributed surplus 11,252 7,995
Deficit (370,378) (351,374)
-----------------------------------------------------------------------
34,219 24,580

-------------------------------------------------------------------------
$ 37,787 $ 41,770
-------------------------------------------------------------------------
-------------------------------------------------------------------------



VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Statements of Operations, Deficit and Comprehensive
Income
(In thousands of Canadian dollars, except per share amounts)
(Unaudited)

-------------------------------------------------------------------------
Period from
December 1,
Three months ended Six months ended 1987 to
May 31, May 31, May 31,
2007 2006 2007 2006 2007
-------------------------------------------------------------------------

Expenses:
Research and
development $ 3,736 $ 11,029 $ 6,759 $ 22,413 $ 235,440
General and
administration 4,888 5,598 8,476 10,490 113,648
Foreign exchange
loss, net 1,092 169 958 172 9,951
-------------------------------------------------------------------------

Loss before the
undernoted (9,716) (16,796) (16,193) (33,075) (359,039)

Interest expense on
senior convertible
notes payable - (304) (5) (787) (1,279)

Accretion in
carrying value of
senior convertible
notes payable (36) (2,280) (728) (4,906) (10,294)

Amortization of
deferred financing
costs (9) (950) (154) (1,580) (3,057)

Loss on
extinguishment of
senior convertible
notes payable (470) (2,701) (1,754) (2,694) (6,749)

Investment income 281 593 633 1,272 12,648

Change in fair value
of embedded
derivatives 256 - 829 - 829
-------------------------------------------------------------------------

Loss for the period
and comprehensive
loss (9,694) (22,438) (17,372) (41,770) (366,941)

Deficit, beginning
of period:
As previously
reported (360,684) (304,051) (351,374) (284,719) (1,510)
Impact of change
in accounting
policy for
financial
instruments on
December 1, 2006 - - (1,632) - -
-----------------------------------------------------------------------
As restated (360,684) (304,051) (353,006) (284,719) (1,510)

Charge for
acceleration
payments on equity
component of senior
convertible notes
payable - (295) - (295) (295)
Impact of change in
accounting policy
for financial
instruments on
December 1, 2006 - - - - (1,632)

-------------------------------------------------------------------------
Deficit, end of
period $(370,378) $(326,784) $(370,378) $(326,784) $(370,378)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted
loss per share $ (0.54) $ (2.59) $ (1.02) $ (4.93) $ -

-------------------------------------------------------------------------
-------------------------------------------------------------------------



VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)

Interim Consolidated Statements of Cash Flows
(In thousands of Canadian dollars)
(Unaudited)

-------------------------------------------------------------------------
Period from
December 1,
Three months ended Six months ended 1987 to
May 31, May 31, May 31,
2007 2006 2007 2006 2007
-------------------------------------------------------------------------
Cash provided by
(used in):
Operations:
Loss for the
period $ (9,694) $ (22,438) $ (17,372) $ (41,770) $(366,941)
Items not
involving cash:
Amortization 127 149 253 298 5,911
Accretion in
carrying value
of senior
convertible
notes payable 36 2,280 728 4,906 10,294
Amortization
of deferred
financing costs 9 950 154 1,580 3,057
Loss on
extinguishment
of senior
convertible
notes payable 470 2,701 1,754 2,694 6,749
Change in fair
value of
embedded
derivatives (256) - (829) - (829)
Stock-based
compensation 890 918 1,453 1,682 13,043
Common shares
issued for
services - - - - 2,485
Unrealized
foreign
exchange loss 1,326 676 1,226 706 10,202
Other - - - - (35)
Change in non-cash
operating working
capital (829) (2,504) (4,304) (8,648) 182
-------------------------------------------------------------------------
(7,921) (17,268) (16,937) (38,552) (315,882)
Financing:
Shares and warrants
issued for cash 17,345 - 17,345 - 326,359
Warrants exercised
for cash - - - - 16,941
Options exercised
for cash - - - - 7,669
Share issue costs (1,443) - (1,440) - (24,646)
Issue (repayment)
of senior
convertible
notes payable,
net (289) - (924) (2,115) 38,512
Restricted cash 289 382 3,325 686 (3,078)
Cash payment on
acceleration
warrants exercise
price - (49) - (49) -
Paid to related
parties - - - - (234)
-----------------------------------------------------------------------
15,902 333 18,306 (1,478) 361,523
Investments:
Purchase of
property and
equipment (11) (14) (41) (14) (2,457)
Purchase of
acquired
technology - - - - (1,283)
Purchases of
marketable
securities - - - (80) (244,846)
Settlement of
forward exchange
contracts - - 10 (259) (4,824)
Maturities of
marketable
securities - 7,653 - 22,877 240,677
-----------------------------------------------------------------------
(11) 7,639 (31) 22,524 (12,733)

Foreign exchange
loss on cash held
in foreign currency (1,349) (1,221) (1,069) (1,539) (2,212)
-------------------------------------------------------------------------
Increase (decrease)
in cash and cash
equivalents 6,621 (10,517) 269 (19,045) 30,696
Cash and cash
equivalents,
beginning of
period 24,075 41,993 30,427 50,521 -
-------------------------------------------------------------------------
Cash and cash
equivalents,
end of period $ 30,696 $ 31,476 $ 30,696 $ 31,476 $ 30,696
-------------------------------------------------------------------------
-------------------------------------------------------------------------


SOURCE Vasogen Inc.

Hey my luck has really turned good, a complete 360 on several that I own. Now just waiting on some of my Oil & Gas stocks to start moving north. VSGN will top over $3.00 this week IMHO.

VSGN seems to want to break through the $2.74 area, it does it will fill that gap & then may run to $3.20(a lot of buying in the pass month)

Amazing its trading lower on the report...Think I will go back to the race track and make my living. This market is just much too Corrupt

Yea!!! Glad I was able to buy 5k shares yesterday... If it goes to $3.15 or higher today then I have to flip it and wait for a shake out. Thank you 3 times... :)

Joe C

Vasogen Reports on Outcome of FDA Meeting

MISSISSAUGA, ON, June 27 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a biotechnology company focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, is pleased to announce the outcome of its meeting with the Food and Drug Administration (FDA) regarding the next steps in the development of its Celacade(TM) technology for the treatment of chronic heart failure in the United States. During the meeting, the Company discussed with the FDA the results of its ACCLAIM study, with a particular focus on the 689-patient subgroup with NYHA Class II heart failure. As a result of the meeting, the FDA has strongly recommended that Vasogen conduct a confirmatory study to support a Pre-market Approval (PMA) filing and also recommended that the Company consider utilizing a Bayesian statistical approach to designing a confirmatory trial. The Bayesian approach involves a specific trial methodology that allows utilization of prior trial results with a confirmatory study to obtain additional information regarding efficacy and safety and has the potential to substantially reduce the number of patients required for a confirmatory study, as well as the cost and duration.

'We are very pleased with the FDA's position regarding the ACCLAIM results of Celacade in NYHA Class II heart failure patients and also that the agency is encouraging us to work with them to develop a protocol for a confirmatory study to support a PMA in the United States,' commented Chris Waddick, President and CEO of Vasogen. 'Having received input from the FDA, we are in a position to fully evaluate our options with respect to a confirmatory trial that could potentially be smaller than the 689-patient NYHA Class II subgroup of patients in ACCLAIM. We are continuing our ongoing dialogue with the FDA, as well as consulting our statistical experts and other advisors to review trial design options, and I look forward to providing an update on this process on our upcoming second quarter conference call.'

The previously reported 2,408-patient, double-blind, placebo-controlled phase III ACCLAIM trial of Celacade in patients with chronic heart failure was completed in 2006. This important study involved 175 clinical centers in seven countries and was designed to assess the ability of Vasogen's Celacade technology to reduce the risk of death or first cardiovascular hospitalization. The primary endpoint for the intent-to-treat study population was not statistically significant (p=0.22); however, the risk reduction directionally favored the Celacade group (hazard ratio=0.92). The key finding from ACCLAIM was in a subgroup of 689 patients who had NYHA Class II heart failure at baseline. In this large subgroup of patients, Celacade was shown to reduce the risk of death or first cardiovascular hospitalization (the primary endpoint for the trial) by 39% (n=689 patients, 216 events, p=0.0003). Celacade was also shown to significantly reduce the risk of death or first cardiovascular hospitalization by 26% in a subgroup of patients in NYHA Classes II - IV with no prior history of heart attack (n=919 patients, 243 events, p=0.02). The ACCLAIM trial also demonstrated that Celacade resulted in a significant improvement in quality of life (as measured by the Minnesota Living with Heart Failure Questionnaire) for the entire study population (n=2,408 patients, p=0.04). Consistent with earlier studies, Celacade was shown to be well tolerated in the ACCLAIM patient population; there were no significant between-group differences for any serious adverse events.

According to the Heart Failure Society of America, heart failure is the only major cardiovascular disease with prevalence and incidence on the rise. Heart failure, which is now often referred to as an epidemic, is estimated to affect 12 million individuals in North America and Europe, with an estimated 4.4 million having NYHA Class II stage disease. The financial burden of heart failure on the healthcare system in the United States alone is estimated to exceed $30 billion per year.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) technology, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade(TM) is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and is preparing to advance VP025, the lead drug candidate from this new class, into phase II development.

Certain statements contained in this press release or elsewhere in our public documents constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or 'forward-looking information' under the Securities Act (Ontario). These statements may include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, plans to advance the development of Celacade(TM), plans to fund our current activities, statements concerning our partnering activities and health regulatory submissions, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'expects', 'plans', 'anticipates', 'believes', 'estimated', 'predicts', 'potential', 'continue', 'intends', 'could', or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of further analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials, delays or setbacks in the regulatory approval process, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the 'Risk Factors' section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Unless otherwise indicated, numerical values indicating the statistical significance ('p-values') of results included in this document are based on analyses that do not account for endpoint multiplicity.

SOURCE Vasogen Inc.

Source: PR Newswire (June 27, 2007 - 6:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

hahaha, yea well with some good news it should pop.Its on my to do list soon.

VSGN still slowly inching up(my lawn goes up faster)

Nice buy on da dip...GLTY

I bought some VSGN on the drop this morning, if it stays up you'll have a nice big "white candle" today.

The way I see it. Great Company = had very bad luck. Turn around could be huge if all comes together.GLTY as well and stay in touch.

Joe

I'm also waiting for a "white candle" on the chart before kicking in some funds....GLTY

Surf, I agree with the your turn around scenario but I feel it will take some more time mostly due to the R/S that took place. I feel that the shares could drop well under $2.00 unless something of materal comes out in news. I am watching for now.
Regards

Joe C.

More info:

Vasogen Will Do 1-For-10 Reverse Split
Monday April 16, 12:04 pm ET
Vasogen to Perform 1-For-10 Reverse Split to Add Institutional Investors, Meet $1 Listing Rule

NEW YORK (AP) -- Canadian biotechnology company Vasogen Inc., which focuses on the chronic inflammation underlying cardiovascular and neurological disease, said Monday it will implement a 1-for-10 reverse stock split.

Beginning Tuesday, the company's stock will trade on the Nasdaq Stock Market under the symbol "VSGND" to reflect the split. It will switch back to the symbol "VSGN" after 20 days.

The company said the split is intended to broaden its institutional investor base and help the company regain compliance with the $1 minimum bid price listing requirement of the Nasdaq.

Vasogen currently has 174.7 million shares outstanding. After the split, it will have 17.5 million shares outstanding.

Shares of Vasogen fell 3 cents to 39 cents in midday trading.

AP
Vasogen Peaks on Grupo Ferrer Agreement
Wednesday April 18, 11:10 am ET
Vasogen Shares Hit New Year High on Grupo Ferrer Collaboration to Bring Heart Drug to Market

NEW YORK (AP) -- Shares of Vasogen Inc. jumped Wednesday after the Canadian biotech drug developer announced a collaboration with Spanish drug and medical device maker Grupo Ferrer Internacional SA to bring the heart failure drug Celacade to market in the European Union.

Under the agreement, the companies will work to bring Vasogen's Celacade technology to European and certain Latin American markets to treat chronic heart failure, Vasogen said.

Vasogen shares rose 39 cents, or 10.7 percent, to $4.04 in morning trading on the Nasdaq Stock Market. Earlier, shares hit a new 52-week high of $4.47. The stock has traded between $3.02 and $3.85 over the past year.

Shares plummeted from the $20 range to the $5 range last June after a clinical trial showed that Celacade only helped a subgroup of patients studied.

Vasogen will receive 45 percent of Ferrer's Celacade revenue over the first five years and 42 percent thereafter, along with payments based on sales milestones. Ferrer will pay for marketing and launch costs.

More than 6 million people in Europe suffer from chronic heart failure.

"Given Grupo Ferrer's proven ability to successfully introduce new healthcare technologies into the large markets of Europe and Latin America, we are extremely excited about this partnership and look forward to the initial commercialization of Celacade later this year," Terry Gregg, Vasogen chairman, president and chief executive, said in a statement.

Last year, Vasogen released data showing that Celacade significantly lowered the risk of death and hospitalization from a heart attack in patients whose heart disease limits their activity severely or confines them to a bed or chair.

Celacade produces an anti-inflammatory response from the immune system by using a patient's own cells to deliver destructive oxidated molecules.

Surf, I really have not followed for 3 months. I see its at a 52 week low. I will look it over in the morning and let you know what I think and thanks for the heads up.

Hi, Stormy are you still looking at VSGN? With the secondary offering over it may have a rebound in the coming weeks. I may take a little bite of it this week(your thoughts)

Vasogen to Trade Under Former NASDAQ Trading Symbol ‘VSGN’ Effective May 15th

Toronto, Ontario - May 03, 2007

Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced that it has received confirmation that its interim trading symbol “VSGND” will be changed back to “VSGN” effective May 15, 2007.

For a period of 20 trading days beginning April 17, 2007, Vasogen’s common stock began trading on a post-reverse split basis on the NASDAQ under the trading symbol “VSGND” – an interim symbol to denote its new status. On May 15, 2007, Vasogen’s common stock will trade on the NASDAQ under its former symbol “VSGN”. The trading symbol for Vasogen on the TSX (“VAS”) has remained unchanged.

Vasogen Raises US$16 Million Through Sale of Common Shares and Warrants

Mississauga, Ontario - May 18, 2007

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that it has entered into definitive purchase agreements with institutional investors to raise US$16 million in gross proceeds through the sale of its common shares at a price of US$3.25, which is a premium to yesterday’s closing stock price on the Nasdaq stock market. Under the terms of the purchase agreements, Vasogen will also issue 5-year warrants to purchase an additional 3.7 million common shares at an exercise price of US$3.16 per share. If all of the 3.7 million warrants are exercised, the Company will receive an additional US$11.7 million in gross proceeds. Following the closing of the financing, expected on or about May 24, 2007 and subject to customary closing conditions, Vasogen will have approximately 22.4 million shares of common stock outstanding. Closing of the transaction will be subject to Toronto Stock Exchange acceptance and usual securities regulatory conditions.

The Company estimates net proceeds from the financing to be approximately US$14.6 million after deducting placement agent fees and the estimated costs associated with the offering. The Company plans to use the net proceeds of this financing for working capital purposes, including but not limited to funding the activities associated with the commercialization of its Celacade™ technology in Europe, the continued development of its Celacade™ technology, and the continued development of its drug, VP025.

Rodman & Renshaw, LLC and JMP Securities LLC are acting as placement agents in connection with this transaction and Rodman & Renshaw, LLC managed the placement and sale of the securities. The placement agents will together receive 295,044 three-year warrants to purchase common shares at US$3.81 per share.